<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6193">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01047189</url>
  </required_header>
  <id_info>
    <org_study_id>00007137</org_study_id>
    <nct_id>NCT01047189</nct_id>
  </id_info>
  <brief_title>Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris</brief_title>
  <official_title>Adherence to ZIANA (Clindamycin Phosphate 1.2% With Tretinoin 0.025%)Gel Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medicis Pharmaceutical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest School of Medicine</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate the effectiveness of two different types
      of topical acne medication. This study will help to determine if one combined medication
      results in better acne improvement than two separate medications for acne.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Measured Adherence to ZIANA Gel or Generic Topical Clindamycin 1% Gel Each Morning Plus Generic Topical Tretinoin 0.025% Cream Each Evening in Subjects With Mild to Moderate Acne</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of prescribed doses taken as measured by a Medication Event Monitoring System (MEMS) cap</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Change (Dynamic Assessment) From Baseline to Week 12 (or End of Treatment) in Total Acne Lesion Count</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ziana gel (clindamycin phosphate 1.2% and tretinoin 0.025%) applied once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Generic clindamycin 1% gel plus tretinoin 0.025% cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clindamycin phosphate 1.2% and tretinoin 0.025%</intervention_name>
    <description>applied once daily for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Ziana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clindamycin 1% gel</intervention_name>
    <description>Topical clindamycin applied each morning for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tretinoin 0.025% cream</intervention_name>
    <description>Tretinoin 0.025% cream each evening for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or Females 12 years of age or older with a diagnosis of mild to moderate acne
             vulgaris.

          -  Subjects must sign written informed consent and agree to come for all study visits.

        Exclusion Criteria:

          -  Use of experimental drugs within 1 month prior to initiation of study therapy.

          -  Pregnant and nursing females will not be allowed in the study, and females of
             childbearing potential will have a pregnancy test at baseline. Females of
             childbearing potential must agree to use approved birth control methods for the
             duration of the study.

          -  Use of systemic retinoids within 2 months of enrollment, use of any topical
             retinoids, systemic antibiotics, nicotinamide, systemic steroids or any other
             medication that may confound the results of the study within 1 month prior to start
             of the study

          -  Use of any other topical medications for acne, including cosmetics containing
             retinol, within 2 weeks prior to study entry.

          -  Any skin condition or disease that may require concurrent therapy or may confound the
             evaluation;

          -  History of hypersensitivity to any of the formulation components;

          -  Facial skin cancer or facial actinic keratosis;

          -  Use of any photosensitizing agents.

          -  Use of isotretinoin within the last 6 months.

          -  Chemical peels, microdermabrasion or laser resurfacing within 3 months of study
             entry.

          -  Crohns disease, ulcerative colitis, or have developed colitis with past antibiotic
             use.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven R Feldman, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences, Dermatology</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>November 9, 2011</lastchanged_date>
  <firstreceived_date>January 11, 2010</firstreceived_date>
  <firstreceived_results_date>July 1, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wake Forest University</investigator_affiliation>
    <investigator_full_name>Steven R. Feldman</investigator_full_name>
    <investigator_title>Professor of Dermatology</investigator_title>
  </responsible_party>
  <keyword>Mild to moderate acne vulgaris</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from IRB approved advertising and the Wake Forest University Health Sciences Dermatology Clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ziana Gel</title>
          <description>Ziana gel (clindamycin phosphate 1.2% and tretinoin 0.025%) applied once daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Clindamycin Plus Tretinoin Applied Separately</title>
          <description>Generic clindamycin 1% gel plus tretinoin 0.025% cream</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ziana Gel</title>
          <description>Ziana gel (clindamycin phosphate 1.2% and tretinoin 0.025%) applied once daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Clindamycin Plus Tretinoin Applied Separately</title>
          <description>Generic clindamycin 1% gel plus tretinoin 0.025% cream</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20.1" lower_limit="13" upper_limit="35"/>
                <measurement group_id="B2" value="26.2" lower_limit="15" upper_limit="40"/>
                <measurement group_id="B3" value="23.1" lower_limit="13" upper_limit="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measured Adherence to ZIANA Gel or Generic Topical Clindamycin 1% Gel Each Morning Plus Generic Topical Tretinoin 0.025% Cream Each Evening in Subjects With Mild to Moderate Acne</title>
        <description>Percentage of prescribed doses taken as measured by a Medication Event Monitoring System (MEMS) cap</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients were analyzed up to end of treatment or last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Ziana Gel</title>
            <description>Ziana gel (clindamycin phosphate 1.2% and tretinoin 0.025%) applied once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clindamycin Plus Tretinoin Applied Separately</title>
            <description>Generic clindamycin 1% gel plus tretinoin 0.025% cream</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Measured Adherence to ZIANA Gel or Generic Topical Clindamycin 1% Gel Each Morning Plus Generic Topical Tretinoin 0.025% Cream Each Evening in Subjects With Mild to Moderate Acne</title>
            <description>Percentage of prescribed doses taken as measured by a Medication Event Monitoring System (MEMS) cap</description>
            <units>Percent of doses</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="88" lower_limit="13" upper_limit="115"/>
                  <measurement group_id="O2" value="61" lower_limit="8" upper_limit="95"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change (Dynamic Assessment) From Baseline to Week 12 (or End of Treatment) in Total Acne Lesion Count</title>
        <time_frame>Baseline to 12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients were analyzed up to end of treatment or last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Ziana Gel</title>
            <description>Ziana gel (clindamycin phosphate 1.2% and tretinoin 0.025%) applied once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clindamycin Plus Tretinoin Applied Separately</title>
            <description>Generic clindamycin 1% gel plus tretinoin 0.025% cream</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Change (Dynamic Assessment) From Baseline to Week 12 (or End of Treatment) in Total Acne Lesion Count</title>
            <units>percentage of lesions</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-51" lower_limit="-80" upper_limit="-23"/>
                  <measurement group_id="O2" value="-32" lower_limit="-66" upper_limit="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.05</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ziana Gel</title>
          <description>Ziana gel (clindamycin phosphate 1.2% and tretinoin 0.025%) applied once daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Clindamycin Plus Tretinoin Applied Separately</title>
          <description>Generic clindamycin 1% gel plus tretinoin 0.025% cream</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation on facial skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven Feldman, MD, PhD</name_or_title>
      <organization>Wake Forest University Health Sciences</organization>
      <phone>336-716-3775</phone>
      <email>sfeldman@wfubmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
